Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 8Active not recruiting 7Terminated 2Recruiting 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 11Thoracic 10Gastrointestinal 10Gynecologic 6Other hematologic neoplasm 5Dermatologic 5Genitourinary 4Breast 3Sarcoma 2Myeloid 2Head & Neck 2CNS 2Tumor-Agnostic 1Plasma cell 1NET 1Endocrine 1

Conditions

Meningioma 1Glioblastoma 1

Interventions

Temozolomide 79Magnetic Resonance Spectroscopy 68Specimen Handling 45Radiotherapy 42Bevacizumab 29Radiosurgery 27Cyclophosphamide 27Radiation 20pembrolizumab 19Blood Specimen Collection 19fludarabine 16Nivolumab 16Irinotecan 15Carboplatin 13Biopsy 13Etoposide 12Vincristine 11Pemetrexed 11Lomustine 11dinutuximab 9Surgical Procedures, Operative 9trametinib 8abemaciclib 8Ipilimumab 8naxitamab 7fluciclovine F-18 7Watchful Waiting 7Topotecan 7Proton Therapy 7Magnetic Resonance Imaging 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Disulfides × CNS × Clear all
NCT02847559 2025-06-27

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Northwestern University

Phase 2 Recruiting
27 enrolled
CNS

Meningioma

NCT06160206 2024-11-19

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Academic and Community Cancer Research United

Phase 2 Recruiting
134 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡